Invea Therapeutics

Invea Therapeutics is a dynamic biotechnology company focused on developing innovative small-molecule oral therapies for immune-mediated inflammatory diseases (IMIDs). Located at 2614 Boston Post Rd, Suite #33AR, Guilford, Connecticut 06437, US, Invea Therapeutics is dedicated to creating oral, safe, and effective therapies that control inflammation, prevent tissue damage, improve quality of life, and achieve long-term disease remission. Their forward-thinking approach combines artificial intelligence (AI) and machine learning with deep expertise to decode the mechanisms driving inflammation in IMIDs.

Invea Therapeutics is advancing two promising product candidates. INVA8001 is poised to enter Phase 2b of clinical development, while INVA8003 is currently in the early stages of preclinical development. These candidates hold the potential to transform the treatment landscape for conditions like atopic dermatitis (AD) and chronic urticaria (CU), addressing the unmet needs of patients with limited or ineffective therapeutic options. INVA8001 is designed as a highly selective and potent inhibitor of chymase, a key mediator of mast cells that drives inflammation, epithelial barrier damage, and fibrosis.

Invea Therapeutics is committed to pioneering advancements in the treatment of immune-mediated inflammatory diseases. The company's dedication to innovation and patient well-being positions Invea Therapeutics as a key player in the biotechnology sector. We invite the management team at Invea Therapeutics to enhance your company's presence on our platform by creating a customized and exclusive company showcase and product listing to further highlight your groundbreaking work.